Celcuity Inc

-0.33 (-1.77%)
Products, Strategic Combinations, Regulatory

Celcuity Says Breast Cancer Clinical Trial Collaboration With MD Anderson, Novartis, And Puma Biotechnology To Study New Drug Regimen

Published: 03/16/2021 20:07 GMT
Celcuity Inc (CELC) - Celcuity Announces Breast Cancer Clinical Trial Collaboration With Md Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen.
Celcuity Inc - Five Clinical Trial Collaborations Are Now in Place and Include Ones With Genentech, Pfizer, Novartis and Puma.
Celcuity Inc - Expects Enrollment to Begin in Q2 of 2021.
Celcuity Inc - Trial Will Evaluate Efficacy and Safety of Novartis' Targeted Therapy Tabrecta and Puma's Nerlynx.